MediGene licenses Veregen in Taiwan
This article was originally published in Scrip
Executive Summary
The German biotech company MediGene has signed another licence and supply agreement for the commercialisation and marketing of Veregen (previously Polyphenon E) ointment for the treatment of genital warts, this time with SynCore Biotechnology in Taiwan.